The committee that decides which health technologies will be adopted by Brazil’s public system is set to examine tomorrow whether to distribute Pfizer’s antiviral Covid pill. Sold under the brand name Paxlovid, the drug gained approval from Brazilian regulators late in March.
The pharmaceutical giant says Paxlovid is highly effective when taken soon after Covid symptoms appear — and laboratory studies suggest the pill is likely to work against the Omicron variant. In Latin America, only Mexico has fully greenlit the drug.
Approval does not mean Paxlovid will be automatically incorporated into Brazil’s health system. That step will depend on negotiations between the government and Pfizer — but prices seem steep. A single patient’s five-day treatment reportedly costs almost the equivalent of a minimum wage in Brazil.
The Abu Dhabi National Oil Company (ADNOC) is no longer interested in buying Novonor's controlling…
Brazilian railway operator Rumo announced a partial interruption of its activities in southern Brazil on…
Welcome to our Tech Roundup, where we bring you the biggest stories in technology and…
For some time, the decisions of Alexandre de Moraes, justice of Brazil’s Supreme Court and…
Panama was once a part of Colombia. Its canal, a monumental engineering achievement of its…
The specialization trend among corporate board members It is not only a matter of perception:…